The disclosure relates to double-stranded ribonucleic acid (dsRNA) compositions targeting ANGPTL7. The invention also relates to methods of using such dsRNA compositions to inhibit expression of ANGPTL7 and to methods of treating ANGPTL7-associated disorders, e.g., glaucoma, using such dsRNA compositions.

Disclosed herein include methods for preventing, inhibiting, reducing, or treating cardiac ischemic injury. The method comprises administering a therapeutic composition comprising a plurality of microRNA (miR) antagonists to a subject before, during, and/or after a cardiac ischemic event. The method can comprise administration of the therapeutic composition as two doses separated by an interval.

Provided are long-acting nerve growth factor (NGF) polypeptides comprising from N-terminus to C-terminus an NGF moiety and an Fe moiety, methods of making, and uses thereof.

The present disclosure provides a method for screening a probiotic strain in promoting reproductive health by using a reproductive disorder model of Caenorhabditis elegans. Cyclophosphamide (CTX) drug intervention is applied to the C. elegans to destroy a normal reproductive system of the C. elegans, thereby obtaining the reproductive disorder model of the C. elegans. Strains capable of significantly improving a reproductive capacity of individuals with reproductive disorders are selected from 3,985 kinds of gene-knockout strains in a Keio gene-knockout library of Escherichia coli; and homologous gene knockout is conducted on a probiotic strain E. coli Nissle 1917 by gene editing, and a probiotic strain with a potential to promote the reproductive health is selected.

The present invention includes compositions and methods for treating diseases or disorders associated with pathological calcification or pathological ossification. In certain embodiments, the diseases or disorders are selected from the group consisting of Generalized Arterial Calcification of Infancy (GACI), Idiopathic Infantile Arterial Calcification (IIAC), Ossification of the Posterior Longitudinal Ligament (OPLL), hypophosphatemic rickets, osteoarthritis, calcification of atherosclerotic plaques, PXE, hereditary and non-hereditary forms of osteoarthritis, ankylosing spondylitis, hardening of the arteries occurring with aging, calciphylaxis resulting from end stage renal disease and progeria.

The present invention relates to a method for treating and/or preventing a disease associated with protein aggregation which comprises the step of preventing protein aggregation associated with RNA removal, by stabilising RNA; or reversing protein aggregation associated with RNA removal, by effectively replacing removed RNA.

A protein selected from the group consisting of Chrdl1, Fam3c, Fam3b and a fragment thereof, or a polynucleotide encoding therefor, for use in treating or reducing the risk of heart disease.

The present disclosure relates to a compound and the use thereof in the preparation of a medicament for treating Alzheimer's disease. The present disclosure provides a method for constructing an animal model of diseases with N-oleoyl-dopamine (OLDA) and the use of the model in drug screening and animal experimental research, wherein the animal model includes at least one of an animal model of neurodegenerative diseases, an animal model of intestinal permeability diseases, and an animal model of inflammatory diseases. The present disclosure is based on the discovery that OLDA has a new use for a neurodegenerative disease, an intestinal permeability disease, and an inflammatory disease, and based on OLDA, compounds that have a therapeutic effect on the above diseases are identified.

Described are alcohol-induced liver cancer model mice, methods of generating the alcohol-induced liver cancer model mice, and methods of using the alcohol-induced liver cancer model mice. Methods of treating alcoholic liver disease, including hepatocellular carcinoma, are also described.

Provided are a novel prophylactic and/or therapeutic drug for an inflammatory disease and a method for searching for the same. A prophylactic and/or therapeutic agent for an inflammatory disease that comprises a substance capable of inhibiting the expression or function of leucine rich alpha 2 glycoprotein (LRG). A method of screening for an anti-inflammatory substance using LRG or an LRG-expressing cell, wherein the inhibition of the expression or function of LRG is used as an index.